Compare · DFTX vs ISPR
DFTX vs ISPR
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Ispire Technology Inc. (ISPR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and ISPR operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.83B, about 48.1x ISPR ($100.4M).
- Over the past year, DFTX is up 398.3% and ISPR is down 39.4% - DFTX leads by 437.7 points.
- DFTX has been more active in the news (29 items in the past 4 weeks vs 2 for ISPR).
- DFTX has more recent analyst coverage (5 ratings vs 1 for ISPR).
PerformanceDFTX+398.31%ISPR-39.37%
2025-07-18+0.00%2026-07-17
- Company
- Definium Therapeutics Inc.
- Ispire Technology Inc.
- Price
- $44.25+0.35%
- $1.74-7.94%
- Market cap
- $4.83B
- $100.4M
- 1M return
- +83.23%
- +4.50%
- 1Y return
- +398.31%
- -39.37%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2023
- News (4w)
- 29
- 2
- Recent ratings
- 5
- 1
Latest DFTX
- Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
- New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
- Definium Therapeutics Announces New Employee Inducement Grants
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
- Chief Legal Officer Sullivan Mark sold $585,750 worth of shares (13,008 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 320,571 units (SEC Form 4) (withholding tax)
- Chief Medical Officer Karlin Daniel sold $451,876 worth of shares (10,035 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 503,282 units (SEC Form 4) (withholding obligation)
- Chief Financial Officer Roberts Brandi sold $135,675 worth of shares (3,013 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 209,487 units (SEC Form 4) (withholding obligation)
- Chief Executive Officer Barrow Robert sold $1,315,236 worth of shares (29,208 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 1,098,246 units (SEC Form 4) to satisfy withholding obligation
- Chief Commercial Officer Wiley Matthew T. sold $129,101 worth of shares (2,867 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 174,633 units (SEC Form 4) (withholding obligation)
Latest ISPR
- SEC Form 8-K filed by Ispire Technology Inc.
- Ispire Technology Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form DEFA14A filed by Ispire Technology Inc.
- SEC Form DEF 14A filed by Ispire Technology Inc.
- SEC Form 10-Q filed by Ispire Technology Inc.
- Ispire Technology Inc. Reports Financial Results for Fiscal Third Quarter 2026
- Ispire Technology Inc. Schedules Fiscal Third Quarter 2026 Earnings Conference Call
- IKETech Wins "Privacy-Centric Age Assurance Solution of the Year," Recognized for Innovation at Global Industry Awards
- IKE Tech Engages FDA on Next-Generation Compliance Infrastructure for ENDS
- SEC Form 4 filed by Fargis John